简介:《数学建模及其应用》是中国工业与应用数学学会及全国大学生数学建模竞赛组委会会刊。杂志刊登以建模为主要内容的应用数学研究成果,用数学建模及方法解决科学、工程技术和经济等应用问题和建模教学研究的成果,以及数学建模竞赛的论坛文章等。读者对象主要是大、中专院校广大师生,数学建模爱好者及应用数学工作者,也包括对数学建模有兴趣的企事业单位和政府人士。特别地,本刊为每年参与数学建模竞赛的广大高校师生提供一个学习、
简介:《数学建模及其应用》是中国工业与应用数学学会及全国大学生数学建模竞赛组委会的会刊。杂志刊登以建模为主要内容的应用数学研究成果,用数学建模及方法解决科学、工程技术和经济等应用问题和建模教学研究的成果,以及数学建模竞赛的论坛文章等。读者对象主要是大、中专院校广大师生,数学建模爱好者及应用数学工作者,也包括对数学建模有兴趣的企
简介:无
简介:AbstractThe rate of multiple pregnancy is increasing, mainly because of the widespread use of assisted reproduction techniques and families’ desire for twins. Twin pregnancy accounts for a higher risk of chromosomal abnormalities, structural malformations, and neonatal adverse events than singleton pregnancy. The presence of artery-vein anastomoses, unbalanced placenta sharing, and abnormal cord insertion in monochorionic twins is associated with twin complications such as twin-to-twin transfusion syndrome, selective intrauterine growth restriction, and twin anemia polycythemia sequence. Although many guidelines and studies have established and improved the processes about the antenatal surveillance and management of twin pregnancy, they also raise more controversies and challenges. This review aims to highlight the international consensus on the antenatal care of twin pregnancies and analyze the controversies and predicaments based on the published International Federation of Gynecology and Obstetrics guidelines and research.
简介:
简介:In2014theAmericanCollegeofCardiology/AmericanHeartAssociationissuedfournewguidelinesforcardiovasculardiseasepreventionthatfocusedoncardiovascularriskassessment,lifestylemanagement,obesitymanagement,andbloodcholesterolmanagement.Thedevelopmentofanatheroscleroticcardiovasculardiseaseriskcalculatorformedthebasisoftheriskassessmentguideline,andthelifestylemanagementguidelinefocusedonrecommendinganevidence-baseddietarypattern.Thebloodcholesterolmanagementguidelinespecificallyidentifiedfourgroupsofpatientsshowntobenefitfrommoderate-intensityorhigh-intensitystatintherapyfrompreviousclinicaltrialsandabandonedtheuseofspecificlow-densitylipoprotein(LDL)cholesterol(LDL-C)goallevelsonthebasisofthelackofclinicaltrialevidence.Therecommendationsfortreatmentwithmoderate-intensityorhigh-intensitystatintherapyarebasedonrigorousevidencefromrandomizedclinicaltrials.Guidancehassincebeenprovidedfortheuseofnonstatintherapies,includingcholesterolabsorptioninhibitorandproproteinconvertasesubtilisin/kexintype9monoclonalantibodytherapywhenadequatereductionofLDL-Clevelsisnotachievedwithmaximallytoleratedstatintherapy.TherecentdevelopmentandapplicationofthesetherapieshaveresultedinremarkablereductionsinLDL-Clevelsthatarewelltolerated,andpreliminaryoutcomedataarepromisinginshowingsubstantialatheroscleroticcardiovasculardiseaseeventreductionsbeyondstatintherapy.